The company's business model involves reducing shareholder risk and achieving a short time to value inflection by in-licensing drugs that are already in human testing for clinical indications with short development timelines, well-defined endpoints for efficacy, and established mechanisms-of-action to ensure predictability and cost efficiency. Ariel Pharmaceuticals focuses on developing therapeutic medicines for people with orphan diseases and acute medical conditions of neurological origin, with a particular emphasis on drugs that are clinic ready. The company seeks to in-license or acquire acute neurology drugs that are already on the market.